Improving diagnostic accuracy in atypical melanocytic tumors using p16 immunohistochemistry and 9p21 fluorescence in situ hybridization: analysis of 206 second opinion cases
Rémi Vergara(Université de Bordeaux), Fanny Beltzung(Université de Bordeaux), B. Vergier(Centre Hospitalier Universitaire de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Arnaud de la Fouchardière(Université Claude Bernard Lyon 1), M. Beylot‐Barry(Université de Bordeaux), Elodie Laharanne(Université de Bordeaux), Jean‐Philippe Merlio(Centre Hospitalier Universitaire de Bordeaux), Mathilde Guyon(Université de Bordeaux), Audrey Gros(Université de Bordeaux)
Cited by 2
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k